Sign in

    Gene Carter • Old Mill Capital Partners

    No verifiable information about Gene Carter as an analyst at Old Mill Capital Partners could be found in publicly available and reputable sources. There is no evidence of a LinkedIn profile, track record, specific company coverage, professional credentials, or career background for an individual by this name at that firm. Attempts to locate details about performance metrics, career timeline, or sector specialization were unsuccessful. It is possible that Gene Carter does not hold a public-facing analyst role at Old Mill Capital Partners or is not affiliated with the firm.

    Gene Carter's questions to IGC Pharma Inc (IGC) leadership

    Gene Carter's questions to IGC Pharma Inc (IGC) leadership • FY 2025

    Question

    Gene Carter of Old Mill Capital Partners inquired about the competitive landscape for Alzheimer's treatments and whether IGC Pharma has enough clinical trial sites to complete its current study.

    Answer

    CEO Ram Mukunda detailed the current treatment landscape, including cognitive enhancers and newer disease-modifying therapies, highlighting challenges with cost and side effects. He positioned IGC-81 as a differentiated oral therapy that is well-tolerated and potentially multifunctional. Mukunda confirmed the existing 22 trial sites are sufficient, citing a new geo-targeting strategy on Facebook that has boosted patient enrollment by 200%, negating the need for additional sites.

    Ask Fintool Equity Research AI